Preclinical Pharmacokinetics (PK) and Pharmacodynamics (PD) Evaluation with Biocytogen
Speaker: John Charpentier, Ph.D, Scientific Content Specialist, Biocytogen Boston Defined pharmacokinetics/pharmacodynamics (PK/PD) and useful parameters to measure them Discussed Biocytogen’s platforms suited for antibody PK/PD studies Introduced humanized mouse models useful for evaluation of PK/PD In vivo case studies and examples Q&A session
Read more
Preclinical Models to Investigate NK Cell-Targeted Immunotherapies
Speaker: Jenna Frame, Ph.D. Manager, Scientific Communications & Marketing, Biocytogen Boston Reviewed the mechanisms driving NK cell activity in the context of immuno-oncology, and the types of NK-targeted immunotherapies currently under investigation Introduced experimental models used to evaluate these immunotherapies, including syngeneic models and xenograft models
Read more
Next-Generation B-NDG Mice: Improved Immunodeficient Models for Research and Discovery
Speaker: John Charpentier, Ph.D, Business Development Manager, Biocytogen Boston Introduced Biocytogen’s highly immunodeficient B-NDG mouse model Discussed our latest, next-generation B-NDG-derived models, such as the B-NDG β2m KO, B-NDG HLA-A2.1, and B-NDG hSIRPα/hCD47 models Described how B-NDG models recapitulate critical aspects of human biology, making them a powerful tool for biomedical research
Read more
Generation and discovery of high affinity antibodies
Speaker: Li Hui, MD, Ph.D. Director, Antibody Discovery & RenMice Licensing, Biocytogen Boston Introduced Biocytogen’s Antibody Discovery Service capabilities, which includes multiple screening technologies and accommodates antibody discovery needs for multiple species, including human, mouse, and rat. Provided proof-of-concept data supporting the robust capabilities of the platform to identify high-quality antibodies with therapeutic potential.
Read more
Design and Screening of Bispecific ADCs Discovered in RenLite Common Light Chain Antibody Mice
Speaker: Yi (Benny) Yang, Ph.D. Chief Scientific Officer, Biocytogen Beijing Introduced Biocytogen’s next-generation fully human bispecific antibody development platform, which has facilitated drug discovery for more than two hundred TAA (tumor associated antigen) targets Analyzed the design, screening and drug discovery of bispecific antibodies and bispecific-ADC drugs in two case studies
Read more
Mouse Models to Investigate New Treatments for Inflammatory Disease
Speaker: Jenna Frame, Ph.D. Manager, Scientific Communications & Marketing, Biocytogen Boston Introduced immune system, cytokines, and autoimmune diseases. Reviewed Modeling Inflammatory Diseases in Wild-Type and Humanized Mice, including multiple Sclerosis/EAE, Rheumatoid Arthritis and Colitis/Inflammatory Bowel Disease. Inflammatory & autoimmune diseases have complex etiologies and mechanisms, but can be modeled in mice. We have established protocols […]
Read moreWebinar Categories
- Antibody Discovery
- Humanized Animal Models
- Others
